ARCHIVES

Ibrutinib Increases OS, PFS Versus Ofatumumab in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

ASCO, Pathologists Publish Guideline On Improving Accuracy Of HER2 Testing

December 29, 2006

Center Seeks HER-2 Positive Breast Cancer Patients

August 29, 2003

Spending Measures Include Provisions On Ethics For NIH Extramural Scientists.

July 11, 2008

In Brief: Bailes Succeeds Lichor As ASCO President; Einhorn Is President-Elect; Durant Honored

May 21, 1999

Phase III Avastin Trial Fails Primary Endpoints

February 28, 2014

Former NCI Lab Deputy Charged With Two Criminal Counts

January 17, 1992